Dermatologic SurgeryIntralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature
Section snippets
Methods
After institutional review board approval, patient data at a hospital-based public university from 1991 to 2006 were retrospectively examined. Eighteen cases of KA injected with intralesional MTX were identified at our institution. Our standard practice for injection is as follows: using a 30-gauge needle, 0.3 to 2.0 mL of MTX in a concentration of either 12.5 or 25 mg/mL is injected at each treatment session. Small KAs are injected at a single central point at the base of the lesion whereas
Results
In all, 38 cases of KA treated with intralesional MTX were identified: 20 cases from the published literature and 18 cases from our institution (Table I). At our institution, 18 patients with an average age of 72.5 years and an average tumor diameter of 2.1 cm were treated with 1 to 3 total injection sessions (mean 2.0 injection sessions). The average cumulative dose of intralesional MTX was 38.2 mg with injections spaced 12 to 38 days (mean 22 days) apart. A complete response was achieved in
Discussion
MTX has an appealing mechanism of action for the potential treatment of rapidly growing tumors, as it inhibits DNA synthesis in actively dividing cells. A folic acid analog, MTX irreversibly binds to dihydrofolate reductase, thereby blocking the formation of tetrahydrofolate and subsequently preventing the downstream synthesis of the purine nucleotide thymidine.25
In our pooled analysis of intralesional MTX for the treatment of KA, none of the patients treated experienced clinically apparent
References (27)
- et al.
Keratoacanthoma centrifugum marginatum of the lower extremity treated with Mohs micrographic surgery
J Am Acad Dermatol
(1994) Keratoacanthomas treated with Mohs' micrographic surgery (chemosurgery): a review of forty-three cases
J Am Acad Dermatol
(1987)- et al.
Radiation therapy of keratoacanthomas: results in 55 patients
Int J Radiat Oncol Biol Phys
(1989) - et al.
Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil
J Am Acad Dermatol
(1986) - et al.
Treatment of keratoacanthomas with intralesional methotrexate
J Am Acad Dermatol
(1991) - et al.
Intralesional methotrexate in keratoacanthoma of the nose
Br J Plast Surg
(1995) - et al.
Treatment of giant keratoacanthoma of the skin of the lower lip with intralesional methotrexate: a case report
J Oral Maxillofac Surg
(2002) The pharmacology of methotrexate
J Am Acad Dermatol
(1991)- et al.
Keratoacanthoma: a clinically distinct variant of well-differentiated squamous cell carcinoma
Adv Anat Pathol
(1998) - et al.
Keratoacanthoma: is it a real entity?
Ann Plast Surg
(1998)
Treatment of a recurrent keratoacanthoma with oral isotretinoin
Int J Dermatol
Radiation therapy of giant aggressive keratoacanthomas
Arch Dermatol
Treatment of keratoacanthomas with curettage
Dermatologica
Cited by (86)
Intralesional methotrexate as non-surgical therapy for giant keratoacanthoma on the nose
2024, British Journal of Oral and Maxillofacial SurgerySuccessful treatment of squamous cell carcinoma with intralesional methotrexate
2022, JAAD Case ReportsCitation Excerpt :Methotrexate is a folic-acid analog that irreversibly inhibits the enzyme dihydrofolate reductase, blocking the synthesis of tetrahydrofolate and, ultimately, preventing the formation of thymidine9; likewise, it increases WWOX gene expression, which promotes caspase activation and apoptosis of cSCC cells.7 Many cases and series have reported on its effectiveness in treating keratoacanthoma10; however, data on intralesional methotrexate in patients with cSCC are scarce.7,11 Recently, a small observational retrospective trial comparing intralesional methotrexate plus surgery versus surgery alone demonstrated a reduction in tumor size that subsequently could facilitate surgery.7
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
2020, European Journal of CancerEvolving Role of Systemic Therapies in Non-melanoma Skin Cancer
2019, Clinical OncologyMultiple Eruptive Keratoacanthomas Secondary to Nivolumab Immunotherapy
2024, Journal of Immunotherapy
Funding sources: None.
Conflicts of interest: None declared.